Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC March Update

The Scottish Medicines Consortium has issued its monthly advice on new medicines.

Zoledronic acid infusion (Aclasta®) has been accepted for restricted use in patients who are unsuitable for or unable to tolerate oral treatment options for osteoporosis.

Salmeterol / fluticasone 50/500 micrograms inhaler (Seretide 500 Accuhaler®) was rejected for the treatment of patients with chronic obstructive airways disease (COPD), with a forced expiration volume in 1 second (FEV1) 50 to <60% predicted normal. The manufacturer did not present a sufficiently robust economic case to gain acceptance.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected medicines should be avoided.

Share 'SMC March Update' on Email Share 'SMC March Update' on Delicious Share 'SMC March Update' on Digg Share 'SMC March Update' on Facebook Share 'SMC March Update' on Google+ Share 'SMC March Update' on reddit Share 'SMC March Update' on StumbleUpon Share 'SMC March Update' on Twitter

atomic-wealth

No Comments to “SMC March Update”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,319 spam comments.

atomic-wealth
fond-illness
summer